期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Medical,ethical,and legal aspects of hematopoietic stem cell transplantation for Crohn’s disease in Brazil 被引量:1
1
作者 Milton Artur Ruiz Roberto Luiz Kaiser Junior +5 位作者 Lilian Piron-Ruiz priscila samara saran Lilian Castiglioni Luiz Gustavo de Quadros Tainara Souza Pinho Richard K Burt 《World Journal of Stem Cells》 SCIE CAS 2020年第10期1113-1123,共11页
Crohn's disease(CD)is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract.The etiology of CD is unknown;however,genetic,epigenetic,environmental,and lifestyle factors could ... Crohn's disease(CD)is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract.The etiology of CD is unknown;however,genetic,epigenetic,environmental,and lifestyle factors could play an essential role in the onset and establishment of the disease.CD results from immune dysregulation due to loss of the healthy symbiotic relationship between host and intestinal flora and or its antigens.It affects both sexes equally with a male to female ratio of 1.0,and its onset can occur at any age,but the diagnosis is most commonly observed in the range of 20 to 40 years of age.CD diminishes quality of life,interferes with social activities,traumatizes due to the stigma of incontinence,fistulae,strictures,and colostomies,and in severe cases,affects survival when compared to the general population.Symptoms fluctuate between periods of remission and activity in which complications such as fistulas,strictures,and the need for bowel resection,surgery,and colostomy implantation make up the most severe aspects of the disease.CD can be progressive and the complications recurrent despite treatment with anti-inflammatory drugs,corticosteroids,immunosuppressants,and biological agents.However,over time many patients become refractory without treatment alternatives,and in this scenario,hematopoietic stem cell transplantation(HSCT)has emerged as a potential treatment option.The rationale for the use of HSCT for CD is anchored in animal studies and human clinical trials where HSCT could reset a patient's immune system by eliminating disease-causing effector cells and upon immune recovery increase regulatory and suppressive immune cells.Autologous HSCT using a non-myeloablative regimen of cyclophosphamide and anti-thymocyte globulin without CD34+selection has been to date the most common transplant conditioning regimen adopted.In this review we will address the current situation regarding CD treatment with HSCT and emphasize the medical,ethical,and legal aspects that permeate the procedure in Brazil. 展开更多
关键词 Crohn disease Hematopoietic stem cell transplant Stem cell therapy Autologous transplant ETHICS TREATMENT
下载PDF
Hematopoietic stem cell transplantation for Crohn's disease: Gaps, doubts and perspectives 被引量:2
2
作者 Milton Artur Ruiz Roberto Luiz Kaiser Junior +3 位作者 Lilian Piron-Ruiz Tatiana Pena-Arciniegas priscila samara saran Luiz Gustavo De Quadros 《World Journal of Stem Cells》 SCIE 2018年第10期134-137,共4页
Crohn's disease(CD) is an inflammatory bowel disease that can affect any site of the digestive system. It occurs due to an immunological imbalance and is responsible for intestinal mucosal lesions and complication... Crohn's disease(CD) is an inflammatory bowel disease that can affect any site of the digestive system. It occurs due to an immunological imbalance and is responsible for intestinal mucosal lesions and complications such as fistulas and stenoses. Treatment aims to stabilize the disease, reducing the symptoms and healing intestinal lesions. Surgical procedures are common in patients. Cell therapy was initially used to treat this disease in patients who also suffered from lymphoma and leukemia and were considered to be good candidates for autologous and allogeneic transplantation. After transplantation, an improvement was also observed in their CD. In 2003, the procedure began to be used to treat the disease itself, and several case series and randomized studies have been published since then; this approach currently comprises a new option in the treatment of CD. However, considerable doubt along with significant gaps in our knowledge continue to exist in relation to cell therapy for CD. Cell therapy is currently restricted to the autologous modality of hematopoietic stem cell transplantation and, experimentally, to mesenchymal stromal cells to directly treat lesions of the anal mucosa. This article presents the supporting claims for transplantation as well as aspects related to the mobilization regime, conditioning and perspectives of cell therapy. 展开更多
关键词 Stem cell therapy Hematopoietic stem cell transplantation TREATMENT Crohn's disease
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部